Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Tax Provisions of $1.0 million for Q1 2026, little changed year-over-year from $1.0 million in Q1 2025, and up 14.94% on a QoQ basis from $870000.0 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 10 years of Tax Provisions data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Tax Provisions changed 0.0% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 4.09% YoY) and the FY2025 annual result came in at $4.0 million, up 33.33% from the prior year.
- Tax Provisions advanced to $1.0 million in Q1 2026 per RARE's latest filing, from $870000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $6.3 million in Q3 2022 and bottomed at -$3.9 million in Q4 2023.
- The 5-year median for Tax Provisions is $732000.0 (2023), against an average of $766235.3.
- The widest annual swing landed in 2022, when Tax Provisions surged 3354.4%; it then tumbled 2151.32% in 2023.
- Tracing RARE's Tax Provisions over 5 years: stood at $189000.0 in 2022, then plunged by 2151.32% to -$3.9 million in 2023, then jumped by 135.7% to $1.4 million in 2024, then sank by 37.14% to $870000.0 in 2025, then climbed by 14.94% to $1.0 million in 2026.
- Per Business Quant, the three latest RARE Tax Provisions figures stand at $1.0 million (Q1 2026), $870000.0 (Q4 2025), and $873000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 870,000.00 |
| Sep 30, 2025 | 873,000.00 |
| Jun 30, 2025 | 947,000.00 |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 303,000.00 |
| Jun 30, 2024 | 858,000.00 |
| Mar 31, 2024 | 455,000.00 |
| Dec 31, 2023 | -3.88 Mn |
| Sep 30, 2023 | 650,000.00 |
| Jun 30, 2023 | 732,000.00 |
| Mar 31, 2023 | 495,000.00 |
| Dec 31, 2022 | 189,000.00 |
| Sep 30, 2022 | 6.29 Mn |
| Jun 30, 2022 | 302,000.00 |
| Mar 31, 2022 | 558,000.00 |
| Dec 31, 2021 | 20,000.00 |
| Sep 30, 2021 | 182,000.00 |
| Jun 30, 2021 | 463,000.00 |
| Mar 31, 2021 | 379,000.00 |
| Dec 31, 2020 | 70,000.00 |
| Sep 30, 2020 | 313,000.00 |
| Jun 30, 2020 | 415,000.00 |
| Mar 31, 2020 | 409,000.00 |
| Dec 31, 2019 | 2.56 Mn |
| Sep 30, 2019 | 293,000.00 |
| Jun 30, 2019 | 213,000.00 |
| Mar 31, 2019 | 216,000.00 |
| Dec 31, 2018 | 126,000.00 |
| Sep 30, 2018 | 247,000.00 |
| Jun 30, 2018 | 102,000.00 |
| Mar 31, 2018 | 39,000.00 |
| Dec 31, 2017 | 29,000.00 |
| Sep 30, 2017 | 4,000.00 |
| Jun 30, 2017 | 14,000.00 |